BY CHRISTOPHER DUE KARLSSON
-
Novo Holdings gets EU approval for investment in UK pharma company
Nevertheless, the investment firm does not wish to discuss the authorization till an offer is wrapped up.
-
Experimental vaccine from Sanofi and J&J disappoints in Phase 3 trial
Unsatisfactory Stage 3 test information has Sanofi currently reserving a huge disability.
-
GN’s hearing aid business falls slightly short of expectations
The firm’s listening devices tasks accomplished sales of DKK 7.10 bn in 2014 and natural development of 10%.
-
Novo wants to be first to market for weight-loss tablets: Applying for approval within “next few months”
The Danish pharmaceutical firm has actually formerly hesitated to talk about the weight-loss tablet computer based upon the exact same energetic compound as Wegovy.
-
Coloplast “strongly disagrees” with verdict on abuse of dominant position in Denmark
Danish competitors authority states that Coloplast’s Danish service has actually abused its leading placement to press rivals out of the marketplace for the sale of ostomy de…
-
Coloplast “strongly disagrees” with verdict on abuse of dominant position in Denmark
Danish competition authority says that Coloplast’s Danish business has abused its dominant position to squeeze competitors out of the market for the sale of ostomy appliances to Da…
-
Novo’s experimental anti-obesity drug achieves 22% weight loss in new trial
Weight-loss prospect amycretin has actually revealed a 22% weight management after 36 weeks in a stage 1b/2a test.
-
Novo Nordisk spent USD 261.5m TV ads for Wegovy in the US last year
Lundbeck’s Rexulti and Novo Nordisk’s Ozempic additionally show up on the leading 10 listing of medicines that invested one of the most cash advertising and marketing o…
-
Biogen has applications accepted for higher doses of muscle wasting drug
The pharmaceutical company is chasing both a faster start-up treatment as well as a higher maintenance treatment.
-
Novo Nordisk has initiated clinical trials for two new weight-loss drugs
Nevertheless, the pharmaceutical firm does not wish to discuss both stage 1 tests, claims its press division.
